Sebia, a global leader in specialty diagnostics, and Warburg Pincus, the pioneer of private equity global growth investing, announces that Warburg Pincus has entered into exclusive negotiations for the potential acquisition of a significant minority stake in Sebia. Sebia is a global specialized In Vitro Diagnostics player providing equipment and reagents for the screening and monitoring of various diseases, primarily in the areas of Oncology (Multiple Myeloma), Diabetes, Hemoglobinopathy, Autoimmune and Infectious diseases and other rare pathologies. The company serves customers in more than 140 countries through a broad installed base and a portfolio of proprietary reagents and instruments.
Read the full article: Sebia and Warburg Pincus Partner to Drive Innovation in Diagnostics //
Source: https://warburgpincus.com/2025/10/16/sebia-and-warburg-pincus-partner-to-drive-innovation-in-diagnostics/